Search

MannKind Corp

Cerrado

SectorSanidad

3.34 -3.75

Resumen

Variación precio

24h

Actual

Mínimo

3.33

Máximo

3.48

Métricas clave

By Trading Economics

Ingresos

-2.4M

-19M

Ventas

19M

109M

P/B

Media del Sector

140.5

55.725

BPA

-0.06

Margen de beneficios

-17.401

Empleados

591

EBITDA

10M

13M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+128.8% upside

Dividendos

By Acuity

Próximas Ganancias

4 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-49M

1.1B

Apertura anterior

7.09

Cierre anterior

3.34

Noticias sobre sentimiento de mercado

By Acuity

63%

37%

273 / 339 Clasificación en Healthcare

MannKind Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

23 sept 2026, 23:01 UTC

MannKind Corp's shares are trading higher in after-market hours, recovering from earlier losses but remain below their 20-day moving average.

22 sept 2026, 23:31 UTC

MannKind Corp is experiencing a notable decline in after-market trading, shifting from a slight gain to a significant loss since Tuesday's close.

21 sept 2026, 23:31 UTC

MannKind Corp's shares are advancing in after-market trading, reflecting a notable rise since Monday's close, though still below the 20-day moving average.

18 sept 2026, 20:06 UTC

MannKind Corp's shares fell sharply after an early spike, remaining below the 20-day moving average and near the lower end of their one-month range.

17 sept 2026, 19:46 UTC

News

MannKind Corp is trading roughly flat as analysts give it an average "Moderate Buy" rating, with seven out of ten firms issuing buy recommendations.

16 sept 2026, 23:52 UTC

MannKind Corp is seeing higher after-market trading, reflecting broader market gains despite concerns over TIC outflows and rising Treasury yields.

15 sept 2026, 22:02 UTC

MannKind Corp shares are lower in after-market hours, reflecting broader market weakness and concerns from a decline in the NY Empire State Manufacturing Index.

14 sept 2026, 19:16 UTC

News

MannKind Corp shares are lower amid mixed analyst ratings and broader market declines, as inflation concerns and supply chain disruptions weigh on sentiment.

11 sept 2026, 19:46 UTC

News

MannKind Corp shares are lower today amid broader market trends and inflation data, marking a third consecutive session of declines.

10 sept 2026, 22:01 UTC

MannKind Corp shares are higher in after-market trading, reflecting notable gains since Thursday's close, though still below the 20-day moving average.

9 sept 2026, 20:01 UTC

Social Media
News

MannKind Corp shares are lower after announcing a licensing deal with Rose Pharma for the development of ROSE-010, an inhaled GLP-1 receptor agonist.

8 sept 2026, 20:07 UTC

News

MannKind Corp's shares are higher today amid mixed analyst ratings, including a downgrade from Zacks and a price target increase from Royal Bank of Canada.

4 sept 2026, 19:36 UTC

MannKind Corp's shares are advancing, recovering from earlier volatility. The stock is currently above its 20-day moving average amid a stable one-month trading range.

3 sept 2026, 23:26 UTC

MannKind Corp shares are higher in after-market trading, reflecting broader market strength amid reduced rate hike expectations. Major indices reported substantial gains.

1 sept 2026, 20:08 UTC

MannKind Corp's shares are lower amid a broader market downturn and rising oil prices, which have heightened inflation concerns and interest rate hike expectations.

31 ago 2026, 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

28 ago 2026, 20:07 UTC

MannKind Corp shares are lower today, extending a three-day decline amid rising U.S. Treasury yields and broader equity market concerns.

27 ago 2026, 19:46 UTC

MannKind Corp. shares are trading roughly flat, with no specific news identified. The stock remains around the middle of its one-month trading range.

26 ago 2026, 20:56 UTC

MannKind Corp shares are higher in after-market trading, reflecting unusual activity. The stock is significantly above its 20-day moving average.

21 ago 2026, 19:41 UTC

MannKind Corp. shares are lower today, trading near the lower end of their one-month range while above the 20-day moving average.

20 ago 2026, 19:51 UTC

Correlated Moves

MNKD lower today amid declines in the biotechnology sector.

19 ago 2026, 23:02 UTC

Correlated Moves

MannKind Corp shares are lower in after-market hours, continuing a downward trend amid broader declines in the biotechnology sector.

18 ago 2026, 22:51 UTC

MannKind Corp shares are lower in after-market hours, with no specific news identified. Broader market sentiment is impacted by rising sovereign bond yields.

17 ago 2026, 19:46 UTC

News

HC Wainwright lowered Q3 2026 EPS estimates for MannKind Corp to -$0.10 but maintained a “Buy” rating. Shares are higher since Friday's close.

14 ago 2026, 19:56 UTC

MannKind Corp. shares are higher today, reversing a four-session decline despite a broader market influenced by a drop in U.S. retail sales.

13 ago 2026, 19:01 UTC

MannKind Corp's shares are lower Thursday, continuing a five-day decline amid mixed economic signals and no specific news identified to explain the drop.

12 ago 2026, 20:06 UTC

MannKind Corp shares are lower today, continuing a decline since Tuesday's close amid shifting U.S. Treasury yields and broader market uncertainties.

11 ago 2026, 23:46 UTC

MannKind shares are higher in after-market trading, reflecting a slight recovery amid a cautious market ahead of the upcoming consumer price index report.

10 ago 2026, 22:56 UTC

MannKind Corp shares are higher in after-market hours following Monday's close, though no specific news was identified to explain the price movement.

7 ago 2026, 23:01 UTC

MannKind Corp shares declined in after-market trading, reflecting notable weakness despite remaining above the 20-day moving average. No specific news was identified.

Comparación entre iguales

Cambio de precio

MannKind Corp previsión

Precio Objetivo

By TipRanks

128.8% repunte

Estimación a 12 Meses

Media 7.985 USD  128.8%

Máximo 13 USD

Mínimo 4.16 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MannKind Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

273 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.